A phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapy

Gynecologic Oncology

Volumn 130, Issue 1, 2013, Pages 19-24

  Wenham, Robert M ^a   Lapolla, James ^b   Lin, Hui Yi ^a   Apte, Sachin M ^a   Lancaster, Johnathan M ^a   Judson, Patricia L ^a   Gonzalez Bosquet, Jesus ^a   Herschberger, Amber ^a   Havrilesky, Laura J ^c   Secord, Angeles Alvarez ^c  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b Gynecologic Oncology   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Bevacizumab; Docetaxel; Ovarian cancer; VEGF

Indexed keywords

BEVACIZUMAB; DOCETAXEL; PLATINUM;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER FATIGUE; CANCER PAIN; CANCER PATIENT; CLINICAL ARTICLE; COLON FISTULA; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOXICITY; DYSPNEA; ENDOCRINE DISEASE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; LEUKOPENIA; METABOLIC DISORDER; NEUROPATHY; NEUTROPENIA; OVARY CANCER; PERITONEUM CANCER; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; TAXOIDS;

EID: 84879092192     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.04.049     Document Type: Article

References (50)

1. B.J. Monk, D.C. Choi, G. Pugmire, and R.A. Burger Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer Gynecol Oncol 96 2005 902 905
2. R.A. Burger, M.F. Brady, M.A. Bookman, G.F. Fleming, B.J. Monk, and H. Huang Incorporation of bevacizumab in the primary treatment of ovarian cancer N Engl J Med 365 2011 2473 2483
3. T.J. Perren, A.M. Swart, J. Pfisterer, J.A. Ledermann, E. Pujade-Lauraine, and G. Kristensen A phase 3 trial of bevacizumab in ovarian cancer N Engl J Med 365 2011 2484 2496
4. C.F.N.J. Aghajanian, T. Rutherford, D.A. Smith, J. Yi, H. Parmar, and L.R. Nycum OCEANS: a randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC) J Clin Oncol 2011 28
5. R.A. Burger, M.W. Sill, B.J. Monk, B.E. Greer, and J.I. Sorosky Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study J Clin Oncol 25 2007 5165 5171
6. S.A. Cannistra, U.A. Matulonis, R.T. Penson, J. Hambleton, J. Dupont, and H. Mackey Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer J Clin Oncol 25 2007 5180 5186
7. A.A. Garcia, H. Hirte, G. Fleming, D. Yang, D.D. Tsao-Wei, and L. Roman Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia J Clin Oncol 26 2008 76 82
8. E.H.F.W.B. Pujade-Lauraine AURELIA: a randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC) J Clin Oncol 2012 30
9. P.G. Rose, J.A. Blessing, H.G. Ball, J. Hoffman, D. Warshal, and K. DeGeest A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study Gynecol Oncol 88 2003 130 135
10. N. Katsumata, R. Tsunematsu, K. Tanaka, Y. Terashima, S. Ogita, and H. Hoshiai A phase II trial of docetaxel in platinum pre-treated patients with advanced epithelial ovarian cancer: a Japanese cooperative study Ann Oncol 11 2000 1531 1536
11. T. Taguchi, H. Furue, H. Niitani, K. Ishitani, R. Kanamaru, and K. Hasegawa Phase I clinical trial of RP 56976 (docetaxel) a new anticancer drug Gan To Kagaku Ryoho 21 1994 1997 2005
12. S. Komiyama, Y. Mizusawa, M. Onouchi, K. Takehara, A. Suzuki, and M. Mikami Effective weekly docetaxel for recurrent ovarian cancer: a case report Int J Gynecol Cancer 13 2003 683 686
13. D.M. Kushner, J.P. Connor, F. Sanchez, M. Volk, J.C. Schink, and H.H. Bailey Weekly docetaxel and carboplatin for recurrent ovarian and peritoneal cancer: a phase II trial Gynecol Oncol 105 2007 358 364
14. T. Safra, R. Bernstein Molho, J. Menzcher, M. Inbar, D. Grisaru, and T. Levy A feasibility study of weekly docetaxel with capecitabine in ovarian cancer: a promising combination of two active drugs with a potential for synergism Chemotherapy 55 2009 298 302
15. D. Gupta, R.L. Owers, M. Kim, D.Y. Kuo, G.S. Huang, and S. Shahabi A phase II study of weekly topotecan and docetaxel in heavily treated patients with recurrent uterine and ovarian cancers Gynecol Oncol 113 2009 327 330
16. A.V. Tinker, V. Gebski, B. Fitzharris, M. Buck, R. Stuart-Harris, and P. Beale Phase II trial of weekly docetaxel for patients with relapsed ovarian cancer who have previously received paclitaxel-ANZGOG 02-01 Gynecol Oncol 104 2007 647 653
17. S. Komiyama, H. Tsuji, S. Asai, J. Dokoh, M. Ishikawa, and M. Mikami A pilot study of weekly docetaxel therapy for recurrent ovarian cancer, tubal cancer, and primary peritoneal cancer Eur J Gynaecol Oncol 26 2005 299 302
18. S.P. Blagden, and S.B. Kaye Docetaxel in the management of ovarian cancer Expert Rev Anticancer Ther 5 2005 203 214
19. A. Berkenblit, M.V. Seiden, U.A. Matulonis, R.T. Penson, C.N. Krasner, and M. Roche A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer Gynecol Oncol 95 2004 624 631
20. F. Terauchi, T. Hirano, H. Taoka, K. Masaki, Y. Yamamoto, and H. Ogura Weekly docetaxel for patients with platinum/paclitaxel/irinotecan-resistant relapsed ovarian cancer: a phase I study Int J Clin Oncol 8 2003 348 351
21. T. Oishi, J. Kigawa, K. Fujiwara, M. Fujiwara, F. Numa, and E. Aotani A feasibility study on biweekly administration of docetaxel for patients with recurrent ovarian cancer Gynecol Oncol 90 2003 421 424
22. E. Tomiak, M.J. Piccart, J. Kerger, S. Lips, A. Awada, and D. de Valeriola Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis J Clin Oncol 12 1994 1458 1467
23. D.E. Cohn, S. Valmadre, K.E. Resnick, L.A. Eaton, L.J. Copeland, and J.M. Fowler Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer Gynecol Oncol 102 2006 134 139
24. B. Gorelik, I. Ziv, R. Shohat, M. Wick, W.D. Hankins, and D. Sidransky Efficacy of weekly docetaxel and bevacizumab in mesenchymal chondrosarcoma: a new theranostic method combining xenografted biopsies with a mathematical model Cancer Res 68 2008 9033 9040
25. K.A. Hotchkiss, A.W. Ashton, R. Mahmood, R.G. Russell, J.A. Sparano, and E.L. Schwartz Inhibition of endothelial cell function in vitro and angiogenesis in vivo by docetaxel (taxotere): association with impaired repositioning of the microtubule organizing center Mol Cancer Ther 1 2002 1191 1200
26. B. Ramaswamy, A.D. Elias, N.T. Kelbick, A. Dodley, M. Morrow, and M. Hauger Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients Clin Cancer Res 12 2006 3124 3129
27. I. Vergote, G.J. Rustin, E.A. Eisenhauer, G.B. Kristensen, E. Pujade-Lauraine, and M.K. Parmar Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic cancer intergroup J Natl Cancer Inst 92 2000 1534 1535
28. T.J. Herzog, J.B. Vermorken, E. Pujade-Lauraine, D.M. Provencher, A. Jagiello-Gruszfeld, and B. Kong Correlation between CA-125 serum level and response by RECIST in a phase III recurrent ovarian cancer study Gynecol Oncol 122 2011 350 355
29. M. Greenwood The natural duration of cancer. Reports on public health and medical subjects London: Her Majesty's Stationery Office 33 1926 1 26
30. E.L. Kaplan, and P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 282 1958 457 481
31. A.A. Garcia, A. Yessaian, H. Pham, G. Facio, L. Muderspach, and L. Roman Phase II study of gemcitabine and docetaxel in recurrent platinum resistant ovarian cancer Cancer Invest 30 2012 295 299
32. A. Polyzos, C. Kosmas, H. Toufexi, N. Malamos, A. Lagadas, and C. Kosmidis Docetaxel in combination with irinotecan (CPT-11) in platinum-resistant paclitaxel-pretreated ovarian cancer Anticancer Res 25 2005 3559 3564
33. K. Ushijima, T. Kamura, K. Tamura, K. Kuzuya, T. Sugiyama, and K. Noda Docetaxel/irinotecan combination chemotherapy in platinum/taxane-refractory and-resistant ovarian cancer: JGOG/WJGOG Intergroup Study Int J Clin Oncol 18 2013 126 131
34. G. Aravantinos, D. Bafaloukos, G. Fountzilas, C. Christodoulou, C. Papadimitriou, and N. Pavlidis Phase II study of docetaxel-vinorelbine in platinum-resistant, paclitaxel-pretreated ovarian cancer Ann Oncol 14 2003 1094 1099
35. D. Matei, R.E. Emerson, J. Schilder, N. Menning, L.A. Baldridge, and C.S. Johnson Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: a Hoosier Oncology Group trial Cancer 113 2008 723 732
36. R.L. Coleman, L.R. Duska, P.T. Ramirez, J.V. Heymach, A.A. Kamat, and S.C. Modesitt Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer Lancet Oncol 12 2011 1109 1117
37. B. Overmoyer, P. Silverman, R. Leeming, R. Shenk, J. Lyons, and N. Ziats Phase II trial of neoadjuvant docetaxel with or without bevacizumab in patients with locally advanced breast cancer Breast Cancer Res Treat 88 Suppl. 1 2004 S106 (Abstract 2088)
38. D.W. Miles, A. Chan, L.Y. Dirix, J. Cortes, X. Pivot, and P. Tomczak Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer J Clin Oncol 28 2010 3239 3247
39. N.S. Azad, C.M. Annunziata, S.M. Steinberg, L. Minasian, A. Premkumar, and C. Chow Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy Cancer 112 2008 1726 1732
40. M. Markman Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy Cancer 113 2008 2832 2833 (author reply 2833-4)
41. C. Ortholan, J. Durivault, J.M. Hannoun-Levi, M. Guyot, C. Bourcier, and D. Ambrosetti Bevacizumab/docetaxel association is more efficient than docetaxel alone in reducing breast and prostate cancer cell growth: a new paradigm for understanding the therapeutic effect of combined treatment Eur J Cancer 46 2010 3022 3036
42. C.J. Sweeney, K.D. Miller, S.E. Sissons, S. Nozaki, D.K. Heilman, and J. Shen The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors Cancer Res 61 2001 3369 3372
43. A. Vacca, D. Ribatti, M. Iurlaro, F. Merchionne, B. Nico, and R. Ria Docetaxel versus paclitaxel for antiangiogenesis J Hematother Stem Cell Res 11 2002 103 118
44. D.S. Grant, T.L. Williams, M. Zahaczewsky, and A.P. Dicker Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere) Int J Cancer 104 2003 121 129
45. L.N. Abaid, K.L. Lopez, J.P. Micha, M.A. Rettenmaier, J.V. Brown III, and B.H. Goldstein Bevacizumab, paclitaxel and carboplatin for advanced ovarian cancer: low risk of gastrointestinal and cardiovascular toxicity Eur J Gynaecol Oncol 31 2010 308 311
46. J.P. Diaz, W.P. Tew, O. Zivanovic, J. Konner, P.J. Sabbatini, and L.A. dos Santos Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma Gynecol Oncol 116 2010 335 339
47. D.L. Richardson, F.J. Backes, J.D. Hurt, L.G. Seamon, L.J. Copeland, and J.M. Fowler Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab? Gynecol Oncol 118 2010 47 51
48. J.L. Tanyi, G. McCann, A.R. Hagemann, G. Coukos, S.C. Rubin, and J.B. Liao Clinical predictors of bevacizumab-associated gastrointestinal perforation Gynecol Oncol 120 2011 464 469
49. G.P. Sfakianos, T.M. Numnum, C.B. Halverson, D. Panjeti, JEt Kendrick, and J.M. Straughn Jr. The risk of gastrointestinal perforation and/or fistula in patients with recurrent ovarian cancer receiving bevacizumab compared to standard chemotherapy: a retrospective cohort study Gynecol Oncol 114 2009 424 426
50. I. Asmane, J.E. Kurtz, A. Bajard, J.P. Guastalla, P. Meeus, and O. Tredan Bevacizumab plus microtubule targeting agents in heavily pre-treated ovarian cancer patients: a retrospective study Bull Cancer 98 2011 80 89